AstraZeneca has entered in a “licensing agreement” with the “Ironwood Pharmaceuticals” on the issue of “exclusive US rights to Zurampic”. The latter is used for treating “hyperuricemia” which results in “uncontrolled gout” problem.
The exclusive U.S. rights on Zurampic will be acquires by Ironwood for using the same in a “fixed-dose combination” which will involve “lesinurad and allopurinol”.
Moreover, AstraZeneca informed that it has plans of submitting the combination of the fixed dose to regulatory authorities for reviewing in the latter half of the year 2016, while Ironwood will make a payment to AstraZeneca for sales and other “milestone” related issues. The amount that will be paid by Ironwood to AstraZeneca is “$265m” in addition to “single-digit royalties on product sales”.
On the other hand, AstraZeneca will be manufacturing Zurampic and supply the same to Ironwood besides supporting some of Ironwood’s services. Furthermore, AstraZeneca will also be undertaking the “FDA post-approval commitment” on behalf of Ironwood.
References:
http://www.digitallook.com/
The exclusive U.S. rights on Zurampic will be acquires by Ironwood for using the same in a “fixed-dose combination” which will involve “lesinurad and allopurinol”.
Moreover, AstraZeneca informed that it has plans of submitting the combination of the fixed dose to regulatory authorities for reviewing in the latter half of the year 2016, while Ironwood will make a payment to AstraZeneca for sales and other “milestone” related issues. The amount that will be paid by Ironwood to AstraZeneca is “$265m” in addition to “single-digit royalties on product sales”.
On the other hand, AstraZeneca will be manufacturing Zurampic and supply the same to Ironwood besides supporting some of Ironwood’s services. Furthermore, AstraZeneca will also be undertaking the “FDA post-approval commitment” on behalf of Ironwood.
References:
http://www.digitallook.com/
